Does meniscus removal affect ACL‐deficient knee laxity? An in vivo study

Stefano Zaffagnini(Istituto Ortopedico Rizzoli), Maurilio Marcacci(Humanitas University), Tommaso Bonanzinga(Istituto Ortopedico Rizzoli), Fabio Cataldi(Pfizer (United States)), Alberto Grassi(Istituto Ortopedico Rizzoli), Cecilia Signorelli(Istituto Ortopedico Rizzoli), Hernán Galán(Instituto Dr. Jaime Slullitel), Laura Bragonzoni(Zambon (Italy)), Ibrahim Akkawi(Istituto Ortopedico Rizzoli)
Knee Surgery Sports Traumatology Arthroscopy
July 1, 2016
10.1007/s00167-016-4222-y
Cited by 32

Related Papers

Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies
|The Lancet|2023|350
Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial
|The Lancet|2017|198
Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study
|Gut|2015|157
Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn’s disease: report of the OPERA study
|Gut|2017|107
Targeting Endothelial Ligands: ICAM-1/alicaforsen, MAdCAM-1
|Journal of Crohn s and Colitis|2018|61